Keywords: Chronic obstructive pulmonary disease (COPD) dual bronchodilator therapy long-acting muscarinic antagonist/long-acting β agonist (LAMA/LABA) Chinese patients Based on the current information, we can conclude that LAMA/LABA FDCs are a suitable and economically viable choice to reduce symptoms and improve the quality of life (QoL) of patients. Methods: Clinical trials on LAMA/LABA in COPD were retrieved in, while important COPD guidelines published in English or Chinese were found in PubMed and Wanfang Database.Ĭonclusions: We recommend the adoption of a clinical pathway in China that includes an assessment and management algorithm that considers the clinical characteristics in China and classifies the phenotypic characteristics of COPD according to a suitable system. LAMA/LABA fixed-dose combinations (FDCs) have become more important in clinical practice and guidelines in China regarding their therapeutic effects and safety. Dual bronchodilator therapy consisting of a long-acting muscarinic antagonist (LAMA) and a long-acting β agonist (LABA) is considered a good choice for COPD patients due to the increased bronchodilation without an increase in adverse events these combinations can fill in the gap in currently available COPD treatments and provide new pharmacotherapy options for Chinese patients. Currently, many Chinese COPD patients are undertreated. Symptoms in Chinese patients are relatively more severe. Objective: To provide an overview of the existing international and Chinese evidence regarding dual bronchodilator inhalation therapy and to make recommendations for the further improvement of chronic obstructive pulmonary disease (COPD) management in clinical practice in China.īackground: COPD is a progressive lung disease that is characterized by persistent airflow limitation and is a major contributor to the disease burden in China. Ji’an Zhou 1^, Jing Zhang 2^, Min Zhou 3^, Jingqing Hang 4^, Min Zhang 5^, Fengfeng Han 6^, Huili Zhu 1^ġ Department of Respiratory and Critical Care Medicine, Huadong Hospital Affiliated with Fudan University, Shanghai, China Ģ Department of Pulmonary Medicine, Zhongshan Hospital Affiliated with Fudan University, Shanghai, China ģ Department of Respiratory Medicine, Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China Ĥ Department of Respiratory Medicine, Shanghai Putuo District People’s Hospital, Shanghai, China ĥ Department of Respiratory and Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China Ħ Department of Respiratory Medicine, Xinhua Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaĬontributions: (I) Conception and design: All authors (II) Administrative support: All authors (III) Provision of study materials or patients: None (IV) Collection and assembly of data: All authors (V) Data analysis and interpretation: All authors (VI) Manuscript writing: All authors (VII) Final approval of manuscript: All authors. Interviews with Outstanding Guest Editors.Policy of Dealing with Allegations of Research Misconduct.
Policy of Screening for Plagiarism Process.
0 kommentar(er)
